EGFR Tyrosine Kinase Inhibitors for NSCLC.
- Author:
Young Chul KIM
1
Author Information
1. Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun, and Division of Pulmonology and Critical Care Medicine, Chonnam National University Medical School, Gwangju, Korea.
- Publication Type:Review
- MeSH:
Adenocarcinoma;
Genes, erbB-1;
Genes, ras;
Korea;
Protein-Tyrosine Kinases*;
Smoke;
Smoking;
Tyrosine*
- From:Journal of Lung Cancer
2005;4(2):71-73
- CountryRepublic of Korea
- Language:English
-
Abstract:
The EGFR Tyrosine kinase inhibitors (TKIs) show significant clinical benefit in selected population with no smoking history, adenocarcinoma or mutations in EGFR gene. Mutations of K-ras gene are associated with resistance to EGFR TKIs. Three published studies of gefitinib experience from Korea are reviewed. Mutations of EGFR gene published up to now and correlation with response to EGFR-TKIs is summarized. This review also discusses the suggested mechanisms of acquired resistance to EGFR TKIs
